Metabolic heterogeneity in patient tumor-derived organoids by primary site and drug treatment
JT Sharick, CM Walsh, CM Sprackling, CA Pasch… - Frontiers in …, 2020 - frontiersin.org
New tools are needed to match cancer patients with effective treatments. Patient-derived
organoids offer a high-throughput platform to personalize treatments and discover novel …
organoids offer a high-throughput platform to personalize treatments and discover novel …
[HTML][HTML] Cellular metabolic heterogeneity in vivo is recapitulated in tumor organoids
JT Sharick, JJ Jeffery, MR Karim, CM Walsh, K Esbona… - Neoplasia, 2019 - Elsevier
Heterogeneous populations within a tumor have varying metabolic profiles, which can
muddle the interpretation of bulk tumor imaging studies of treatment response. Although …
muddle the interpretation of bulk tumor imaging studies of treatment response. Although …
Autofluorescence imaging of treatment response in neuroendocrine tumor organoids
AA Gillette, CP Babiarz, AR VanDommelen, CA Pasch… - Cancers, 2021 - mdpi.com
Simple Summary Gastroenteropancreatic neuroendocrine tumors (GEP-NET) account for
roughly 60% of all neuroendocrine tumors, and low/intermediate grade human GEP-NETs …
roughly 60% of all neuroendocrine tumors, and low/intermediate grade human GEP-NETs …
Sample preparation strategies for high‐throughput mass spectrometry imaging of primary tumor organoids
J Johnson, JT Sharick, MC Skala… - Journal of mass …, 2020 - Wiley Online Library
Patient‐derived 3D organoids show great promise for understanding patient heterogeneity
and chemotherapy response in human‐derived tissue. The combination of organoid culture …
and chemotherapy response in human‐derived tissue. The combination of organoid culture …